Tumor models are critical for our understanding of cancer and the development of cancer therapeutics. As now published in BMC Genomics, TRON researchers utilized next-generation sequencing, bioinformatics and immuno-informatics to create an integrated mouse solid tumor mutanome, transcriptome and immunome, providing an overdue analysis of an epithelial mouse tumor, the CT26 colon carcinoma cell line.
In sharp contrast to the frequent use of CT26 in drug development, there has been no comprehensive studies of the genome and transcriptome of CT26. TRON researchers found that the patterns of mutations in onco-relevant genes, the gene expression signatures and the regulated pathways in CT26 cells are in agreement with their origin in colon epithelia and share features with human primary CRCs.
The mutations and expression profiles are similar to those reported for sporadic, undifferentiated, therapy-refractory, metastasis-prone human CRC. Moreover, they identified non-synonymous SNVs with predicted MHC class I binding capability which, together with the robust MHC class I expression of CT26 cells, provide a valuable resource for use of the CT26 model system to develop immunotherapeutic approaches.
The study by John Castle et al. provides an overdue genomic and transcriptomic analysis of one of the most frequently used cell lines for drug development and forms the basis for the rationale design of pre-clinical studies using this model for drug development based on detailed molecular knowledge.